Go-ahead for Possis stroke trials:
This article was originally published in Clinica
Possis Medical has the go-ahead for US trials of its AngioJet clot-busting system for treating stroke caused by blocked carotid arteries. Feasibility studies will consist of 10 patients at two sites. The company has filed a humanitarian device exemption application with the FDA to sell its Perma-Flow coronary bypass graft to a limited number of patients. This will not necessitate new trials of the device as reported in Clinica No 782, p 19.
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.